Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

    -- our ability to borrow additional amounts under the loan from Bay City
       Capital, which is subject to the discretion of Bay City Capital;
    -- our ability to obtain necessary financing in the near term, including
       amounts necessary to repay the loan from Bay City Capital by the
       September 14, 2009 maturity date (or earlier if certain repayment
       acceleration provisions are triggered);
    -- our ability to control our operating expenses;
    -- our ability to comply with covenants included in the loan from Bay
       City Capital;
    -- our ability to maintain the listing of our common stock on NASDAQ;
    -- our failure to timely recruit and enroll patients for the FDG-PET
       clinical trial, as well as any future clinical trial;
     -- our failure to obtain sufficient data from enrolled patients that can
       be used to evaluate VIA- 2291, thereby impairing the validity or
       statistical significance of our clinical trials;
    -- our ability to successfully complete our clinical trials of VIA-2291
       on expected timetables and the outcomes of such clinical trials;
    -- complexities in designing and implementing cardiovascular clinical
       trials using histological examinations, measurement of biomarkers,
       medical imaging and atherosclerotic plaque bioassays;

'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DALLAS , July 23, 2014 ... LLC ("Plaintiff") filed suit in the 116 ... Dallas, Texas , against RegenLab USA, ... Current and Prospective Business Relationships through false ... interference; and, Business Disparagement through libel, ...
(Date:7/23/2014)... Use of Risk Evaluation and Mitigation Strategies (REMS) and ... results in $5.4 billion in lost savings annually, according ... economic consulting firm Matrix Global Advisors (MGA). ... Required by the Food and Drug Administration (FDA) for ... to improve drug safety by ensuring that the benefits ...
(Date:7/23/2014)... 23, 2014 PositiveID Corp. (OTCQB: PSID), based ... is an emerging player in the bio-threat detection ... detection and rapid medical testing. The Company,s proprietary ... Autonomous Networked Detector), was developed under contract with ... & Technology directorate, and $30 million of contract ...
Breaking Medicine Technology:New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2
... The U.S. Food and Drug Administration today ... metastatic breast cancer who have received at least ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... the second leading cause of cancer related death ...
... Millennium Research Group (MRG), the global authority ... latest peripheral vascular research data for multiple geographies, ... Latin America. MRG,s peripheral vascular reports ... artery disease, including stenting, percutaneous transluminal balloon angioplasty, ...
Cached Medicine Technology:FDA Approves New Treatment Option for Late-Stage Breast Cancer 2New Peripheral Vascular Device Market Research Data Covering Multiple Geographies Released by Millennium Research Group 2
(Date:7/23/2014)... TX (PRWEB) July 23, 2014 Ticket ... vs. AS Roma tickets in Dallas, TX at the ... eight team tournament held in the United States and Canada ... the world including teams from La Liga, Serie A, English ... year are Manchester United, Manchester City, Olympiacos, Inter Milan, Liverpool, ...
(Date:7/23/2014)... 23, 2014 Recently, Agebc.com has launched ... the company is announcing a promotion of wedding dresses. ... will end at the end of this month. , ... popular styles, like A-line, mermaid, ball-gown, empire, and more. ... and other special-occasion dresses for women, and the company ...
(Date:7/23/2014)... Battle Creek, MI (PRWEB) July 23, 2014 ... treatment program that gets clients off to a great ... they can believe in, has launched a new Internet ... , “Many people are surprised to learn that Internet ... sexual addiction or drug addiction, but that it’s trapping ...
(Date:7/23/2014)... Pallarito HealthDay Reporter TUESDAY, ... for Obamacare, two federal appeals courts arrived at completely different ... millions of Americans who bought health insurance through the federal ... is headed for a showdown before the U.S. Supreme Court. ... Court for the District of Columbia Circuit said that the ...
(Date:7/23/2014)... arriving at the emergency department, the drug ketamine ... rapid, life-saving intubation, despite decades-old studies that suggested ... a systematic review of 10 recent studies of ... drug" are published online in Annals of ... on Intracranial and Cerebral Perfusion Pressure and Health ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Slashes Ticket Prices on all AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Slashes Ticket Prices on all AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 2Health News:2 Courts, 2 Different Decisions on Key Obamacare Provision 3Health News:Ketamine can be a wonder drug for ER patients and their physicians 2
... (HealthDay News) -- A gene variant associated with asthma ... of researchers working together in a new national collaboration ... was not present in European Americans and may be ... in black Americans. The researchers, analysis of data ...
... August issue of the Journal of the American College ... in head computed tomography (CT) scans. Head CT is the ... the total number of CT examinations. Magnetic resonance imaging ... a vast majority of brain and spinal indications. However, CT ...
... (HealthDay News) -- Several biomechanical differences appear to separate ... could the study identify ways for recreational golfers to ... said the Stanford University School of Medicine team that ... cameras to analyze the full golf swings -- from ...
... Laxenburg, Austria 28 July 2011 -- Future trends ... improvements in both the quality and quantity of education, ... do not explicitly include education in their analysis may ... journal Science (July 29 2011). ...
... FRIDAY, July 29 (HealthDay News) -- A growing number of ... in which they spend three or more nights together each ... own homes, a new study shows. "Instead of following ... to engage in romantic ties on their own terms ...
... will begin a Phase 1 clinical trial on a ... represents the first new class of anti-TB drugs in ... both drug-susceptible and drug-resistant TB. The study is ... awarded from the National Institutes of Health through the ...
Cached Medicine News:Health News:Education -- a key determinant of population growth and human well-being 2Health News:Education -- a key determinant of population growth and human well-being 3Health News:Even Living Together Is Too Much Commitment for Today's Couples 2
... The Cadwell Cascade is a powerful, multi-modality system ... free-run EMG, stimulated EMG, EEG, and train of ... with portability as a priority. The base weighs ... weighs just 13 lbs. A desktop PC-based system ...
... Endeavor is a neuromonitoring system especially ... monitoring. Endeavor amplifier has 16 channels and ... active electrode inputs. Each channel can be ... or a true differential channel. Endeavor amplifiers ...
... Katena Products, Inc. is the ... dedicated exclusively to ophthalmic surgical ... to over 7,000 customers in ... a global network of distributors, ...
... Blood glucose, medication, food, exercise, stress . ... a diabetes patients overall health. Unfortunately, its ... this vital information on a daily basis. ... day-to-day results or submit the information to ...
Medicine Products: